www.fdanews.com/articles/197013-japan-approves-gileads-remdesivir-as-covid-19-treatment
![Purple_Approved_Stamp.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/Purple_Approved_Stamp.gif?t=1576639773&width=430)
Japan Approves Gilead’s Remdesivir as COVID-19 Treatment
May 8, 2020
Japan has approved Gilead’s remdesivir for treatment of COVID-19, making it the first country to officially approve the antiviral drug for the coronavirus.
Gilead filed for fast-track approval of the drug on Monday in Japan, just days after the FDA granted remdesivir an Emergency Use Authorization (EUA) for severe COVID-19 patients in the U.S. Japan’s approval reference the EUA issued by the FDA.
Japanese health officials said the drug will be given to patients with severe COVID-19 symptoms.